Medically Reviewed Why Dialysis Patients Get Heart Attacks: The CKD-Heart Link
If you or someone you love is on dialysis and has been told to “watch your heart,” that advice carries more clinical weight than most patients realise. Cardiovascular mortality is 10-20 times higher in dialysis patients than in the general population, a number that reflects how deeply CKD and heart disease are biologically connected, not just coincidentally linked. An estimated 40-50% of all deaths in CKD stages 4 and 5 are cardiovascular, compared with only 26% in those with normal kidney function. Most dialysis patients in India are never told they are statistically more likely to die from a heart event than from kidney failure itself. That gap in awareness has real consequences.
In this blog, we cover why the kidney-heart relationship is bidirectional, how kidney failure directly causes heart attacks, what left ventricular hypertrophy means for your long-term risk, and what the evidence supports for reducing that risk.
Key Takeaways:
- Up to 40% of CKD patients who start dialysis already have heart failure; the cardiac damage begins well before dialysis.
- Protein-bound uremic toxins that cause coronary artery damage are poorly removed by standard dialysis techniques.
- Left ventricular hypertrophy reaches a prevalence of 70-80% in kidney failure patients, and is a direct, independent predictor of cardiac death.
Quick Answer: CKD and heart disease are bidirectional; kidney failure causes heart attacks, LVH, and sudden cardiac death through uremic toxins, volume overload, and chronic inflammation, with cardiovascular mortality 10-20 times higher in dialysis patients.
Quick Links
The CKD-Heart Connection: Why It Is Bidirectional
Kidney and heart function are intrinsically linked; dysfunction in one or gan induces pathological changes in the other, a relationship formally termed cardiorenal syndrome. Chronic kidney diseases (CKD) and heart failure are closely interconnected, each condition significantly increasing the risk of developing the other, with coexistence worsening prognosis and raising mortality rates. Cardiovascular disease accounts for 40-50% of all deaths in CKD stages 4 and 5, compared with only 26% in those with normal kidney function. Most CKD patients are statistically more likely to die from a cardiac event than from kidney failure itself, a fact rarely communicated at dialysis initiation in India.
Can Kidney Disease Actually Cause a Heart Attack?
Yes, kidney disease directly causes heart attacks, and the mechanism goes well beyond shared risk factors like diabetes or high blood pressure. The incidence of myocardial infarction is 5-15 times higher, and cardiovascular mortality is 30 times higher in dialysis patients than in the general population.
Here are some of the critical factors where kidney disease can cause heart attack:
- Protein-bound uremic toxins, indoxyl sulphate and p-cresyl sulphate, induce vascular inflammation, endothelial dysfunction, and vascular calcification, and are poorly removed by current dialysis techniques.
- Indoxyl sulphate increases oxidative stress, decreases nitric oxide production, and accelerates arterial inflammation, silently damaging coronary artery walls long before any cardiac event occurs.
- Atherosclerotic plaques are present in up to 30% of patients with CKD, driven by mechanisms that operate independently of conventional cholesterol pathways. These plaques calcify more readily and rupture more unpredictably than in the general population [1].
- Vascular calcification restricts coronary supply: Indoxyl sulphate correlates directly with vascular stiffness and congestive heart failure in end-stage renal disease patients.
- 90% of CKD patients will suffer or die of cardiovascular complications, and the major causes of cardiac death are myocardial infarction, heart failure, and sudden cardiac death.
Now, let’s understand left ventricular hypertrophy and why it is a silent cardiac crisis for dialysis patients.
Left Ventricular Hypertrophy: The Silent Cardiac Crisis in Dialysis
Left ventricular hypertrophy occurs early in CKD and reaches a prevalence of 70–80% in patients with kidney failure, making it the most common structural cardiac change in dialysis patients, and one of the least discussed.
- LVH develops early and worsens with CKD progression, reflecting the close interplay between renal dysfunction and cardiac remodelling. In patients with new dialysis, the prevalence of LVH is 75% [2].
- Arterial stiffness causes concentric LVH, while volume overload between sessions causes eccentric remodelling. Anaemia adds a third pressure; the heart enlarges to compensate for poor oxygen delivery.
- A significant relationship exists between anaemia and LV hypertrophy; the mean LV mass index was highest in the lowest haemoglobin quartile and fell progressively as haemoglobin improved.
- Myocardial fibrosis in CKD leads to collagen deposition between cardiomyocytes, maladaptive ventricular hypertrophy, and subsequent heart dilation. Regression of LVH reduces heart failure incidence and sudden arrhythmic death.
- Intensive haemodialysis reduces left ventricular mass by 8-10% relative to three sessions per week. In India, where twice-weekly dialysis is standard, cumulative volume overload between sessions is a direct, modifiable driver of LVH.
Why Dialysis Itself Does Not Fully Protect the Heart
Starting dialysis does not reset the cardiovascular clock; in CKD and heart disease, structural damage that precedes dialysis persists, and the dialysis process itself introduces new cardiac risks that are distinct from kidney failure alone.
1. Protein-Bound Toxins Remain in the Blood
Protein-bound uremic toxins, such as indoxyl sulphate and p-cresyl sulphate, are poorly removed by current dialysis techniques due to their size and protein binding. Despite good control of traditional cardiovascular risk factors, CV mortality in CKD patients remains high; increased uremic toxin concentrations at least partially explain this persistent discrepancy.
2. Each Session Causes Myocardial Stunning
Intradialytic hypotension triggers hypovolemic stress, leading to myocardial stunning, cerebral ischaemia, and organ dysfunction. These recurrent ischaemic insults result over time in irreversible fibrotic changes, chronic heart failure, arrhythmias, and sudden cardiac death. This process occurs even in patients without pre-existing coronary artery disease.
3. Volume Overload Accumulates Between Sessions
In India, where twice-weekly dialysis is standard, patients carry 3-4 days of fluid accumulation before their next session. Volume overload is independently associated with left ventricular hypertrophy: as relative overhydration increases, left ventricular mass index increases in a measurable, dose-dependent pattern. This is a direct, modifiable cardiovascular risk amplifier that twice-weekly schedules worsen.
4. Mineral Bone Disorder Calcifies Coronary Arteries
Calcium and phosphate abnormalities play central roles in the pathogenesis of atherosclerosis in patients with renal disease alongside uremic toxins and anaemia. Elevated calcium-phosphate product actively deposits in coronary arteries and heart valves, a process that does not pause between dialysis sessions and worsens measurably when phosphate control is poor.
5. Pre-Existing Cardiac Damage Does Not Reverse
Long-term consequences of end-stage kidney disease, including inflammation, cardiovascular disease, and asthenia, are not reduced and may even worsen with haemodialysis therapy. LVH, myocardial fibrosis, and vascular calcification established before dialysis initiation remain structurally present; dialysis clears waste but does not repair the cardiac remodelling that kidney failure has already caused.
Reducing Heart Risk in CKD: What the Evidence Supports
Starting dialysis does not reset the cardiovascular clock. In CKD and heart disease, structural damage that precedes dialysis persists, and the dialysis process itself introduces new cardiac risks that are distinct from kidney failure alone.
Protein-Bound Toxins
Protein-bound uremic toxins, such as indoxyl sulphate and p-cresyl sulphate, are poorly removed by current dialysis techniques due to their size and protein binding. Despite good control of traditional cardiovascular risk factors, CV mortality in CKD patients remains high; increased uremic toxin concentrations at least partially explain this persistent discrepancy.
Each Session Causes Myocardial Stunning
Intradialytic hypotension triggers hypovolemic stress, leading to myocardial stunning, cerebral ischaemia, and organ dysfunction. These recurrent ischaemic insults result over time in irreversible fibrotic changes, chronic heart failure, arrhythmias, and sudden cardiac death. This process occurs even in patients without pre-existing coronary artery disease.
Volume Overload
In India, where twice-weekly dialysis is standard, patients carry 3-4 days of fluid accumulation before their next session. Volume overload is independently associated with left ventricular hypertrophy: as relative overhydration increases, left ventricular mass index increases in a measurable, dose-dependent pattern. This is a direct, modifiable cardiovascular risk amplifier that twice-weekly schedules worsen.
Mineral Bone Disorder
Calcium and phosphate abnormalities play central roles in the pathogenesis of atherosclerosis in patients with renal disease alongside uremic toxins and anaemia. Elevated calcium-phosphate product actively deposits in coronary arteries and heart valves, a process that does not pause between dialysis sessions and worsens measurably when phosphate control is poor.
Pre-Existing Cardiac Damage
Long-term consequences of end-stage kidney disease, including inflammation, cardiovascular disease, and asthenia, are not reduced and may even worsen with haemodialysis therapy. LVH, myocardial fibrosis, and vascular calcification established before dialysis initiation remain structurally present; dialysis clears waste but does not repair the cardiac remodelling that kidney failure has already caused.
Also read: Hemodiafiltration vs Hemodialysis: A Clear Guide for Kidney Care.
Final Thoughts
The relationship between CKD and heart disease is not something that develops after dialysis starts; it begins the moment kidney function starts to decline, and it progresses silently until a cardiac event makes it visible. Blood pressure control, phosphate management, anaemia treatment, and fluid restriction between sessions are the most direct, evidence-based steps that reduce cardiovascular risk in dialysis patients, and all four are actionable at your very next session. Ask your nephrologist for an echocardiogram if you have not had one since starting dialysis; LVH is common, treatable in part, and rarely screened for without a specific request.
Emerging agents such as SGLT2 inhibitors and mineralocorticoid receptor antagonists have shown efficacy in slowing CKD progression and reducing cardiovascular events; discuss with your care team whether these options are appropriate for your clinical profile. At Eskag Sanjeevani dialysis centres, where cardiovascular risk in dialysis patients receives structured attention alongside standard renal care, catching these changes early is what separates a manageable trajectory from an avoidable crisis.
References
- Zhao X, Sun H, Li W. Efficacy and safety of different systemic drugs in the treatment of uremic pruritus among hemodialysis patients: a network meta-analysis based on randomized clinical trials. Front Med (Lausanne). 2024 Apr 5;11:1334944. doi: 10.3389/fmed.2024.1334944. PMID: 38646551; PMCID: PMC11026555.
- Swarna SS, Aziz K, Zubair T, Qadir N, Khan M. Pruritus Associated With Chronic Kidney Disease: A Comprehensive Literature Review. Cureus. 2019 Jul 28;11(7):e5256. doi: 10.7759/cureus.5256. PMID: 31572641; PMCID: PMC6760874.
The incidence of myocardial infarction is 5-15 times higher in dialysis patients than in the general population, driven by uremic toxin accumulation, endothelial dysfunction, and vascular calcification. Most CKD patients are more likely to die from a cardiovascular event than from kidney failure itself.
Cardiorenal syndrome is the bidirectional relationship where dysfunction in the heart or kidney directly worsens the other organ, compounding overall clinical outcomes. Up to 40% of CKD patients already have heart failure at dialysis initiation, and new heart failure develops at an annual incidence of 20% among those who do not.
Uremic toxins, vascular calcification, chronic inflammation, and traditional risk factors together create a disproportionately high cardiovascular burden in dialysis patients. Protein-bound toxins that damage coronary arteries are poorly removed by standard dialysis; cardiovascular toxin exposure continues between every session.
Long-term cardiovascular consequences of kidney failure are not reduced and may worsen with haemodialysis therapy. Dialysis clears small, water-soluble toxins but does not reverse LVH, myocardial fibrosis, or vascular calcification already present at the initiation of dialysis.
KDIGO 2024 recommends a systolic blood pressure target below 120 mmHg and expanded use of SGLT2 inhibitors, with reductions in heart failure hospitalisation and kidney disease progression. Anaemia treatment, phosphate control, and fluid restriction between sessions are all direct, evidence-based steps that reduce cardiovascular risk in dialysis patients.